Lucid Diagnostics Inc.
HealthcareNASDAQ:LUCD · NASDAQ Global Market
-$0.02 today
Vol 0.83M · Avg 0.83M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-530.4%
avg 107.4%
ROIC
-135.1%
avg -88.3%
ROA
-143.4%
avg -979.5%
Analysis
ROIC is currently the strongest return metric at -135.1% versus its period average of -88.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Lishan Aklog | Chairman & Chief Executive Officer | $450,000.00 | — | 60 | $3.64M | 3.55% |
Shaun O'Neill | President & Chief Operating Officer | $375,000.00 | — | 44 | $1.45M | 1.41% |
Michael Adam Gordon | General Counsel & Secretary | $312,500.00 | — | 51 | $1.00M | 0.98% |
Dennis McGrath | Chief Financial Officer | $303,750.00 | — | 69 | $1.03M | 1.01% |
Amitabh Chak | Co-founder & Strategic Advisor | $14,535.00 | — | — | — | — |
Joseph Willis | Co-founder & Strategic Advisor | $14,535.00 | — | — | — | — |
Sanford D. Markowitz | Co-founder & Strategic Advisor | $14,535.00 | — | — | — | — |
Helen Moinova | Co-founder & Strategic Advisor | $14,535.00 | — | — | — | — |
Brian J. deGuzman | Chief Technology & Compliance Officer | — | — | 61 | — | — |
Deepika A. Lakhani | Senior Vice President, Chief Regulatory & Quality Officer | — | — | — | — | — |
Danielle W. Scelfo | Senior Vice President of Market Access & Government Affairs | — | — | — | — | — |
Suman Verma | Senior VP & Chief Scientific Officer | — | — | — | — | — |
Matthew Riley | Director of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$347,109.50
Sells
0
$0.00
Net Sentiment
+$347,109.50
Net buying
Most Active
Matheis Dennis
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| May 20, 2026 | Matheis Dennis Direct | Buy | 245.0K | $1.00 | $245,269.50 | |
| Aug 20, 2025 | Matheis Dennis Direct | Buy | 100.0K | $1.02 | $101,840.00 |
Analysis
Insiders reported 2 buys worth $347,109.50 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $347,109.50. Matheis Dennis was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +84.1% (8yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +84.1% (8yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Anteris Technologies Global Corp.
NASDAQ:AVR
$336.61M
Opus Genetics, Inc.
NASDAQ:IRD
$328.84M
Apyx Medical Corporation
NASDAQ:APYX
$196.39M
AVITA Medical, Inc.
NASDAQ:RCEL
$97.14M
Seer, Inc.
NASDAQ:SEER
$94.57M
Owlet, Inc.
NYSE:OWLT
$84.14M
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
$79.77M
Scilex Holding Company
NASDAQ:SCLX
$72.18M
SkyAI, Inc.
STSS
$47.61M
Incannex Healthcare Limited
IXHL
$43.99M
Who manages LUCD?
Lucid Diagnostics Inc. (LUCD) lists 13 active executives. The top listed executive is Dennis McGrath, Chief Financial Officer.
Are LUCD insiders buying or selling?
Recent insider activity shows net buying of $30.28M.
Explore More
Continue the stock analysis
Jump to another research area for this company.